ContributorsPublishersAdvertisers

Dr. Westin on Patient-Reported Outcomes From the TRANSFORM Study in R/R LBCL

onclive.com
 2022-01-24

Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma. Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas...

www.onclive.com

Comments / 0

Comments / 0